Patient Convenience Study (RE-SONANCE)


Phase N/A Results N/A

Summary of Purpose

The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 milligrams or 150 milligrams twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 22 June 2017.

11 Nov 2015 11 Nov 2015 1 Jun 2017 1 Jun 2017 1 Jun 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics



Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample